NPS Announces Extension of R&D Collaboration With AstraZeneca
Advertisement
NPS Pharmaceuticals, Inc. announced an extension of its strategic alliance with AstraZeneca to discover, develop and market new drugs targeting metabotropic glutamate receptors (mGluRs) for the treatment of various central nervous system and gastrointestinal disorders.
Under the terms of the extended agreement, the companies will continue their research collaboration for a minimum of three years with options to extend for an additional two years. AstraZeneca is presently engaged in Phase 1 clinical development activities with an mGluR active molecule discovered together with NPS.